Aliases & Classifications for Neuropathy

MalaCards integrated aliases for Neuropathy:

Name: Neuropathy 12 6 15 39 17 70
Peripheral Neuropathy 12 70
Peripheral Neuropathies 15

Classifications:



External Ids:

Disease Ontology 12 DOID:870
NCIt 50 C4731
SNOMED-CT 67 42658009
ICD10 32 G62.9
UMLS 70 C0031117 C0442874

Summaries for Neuropathy

Disease Ontology : 12 A nervous system disease that is located in nerves or nerve cells.

MalaCards based summary : Neuropathy, also known as peripheral neuropathy, is related to neuropathy, congenital hypomyelinating, 1, autosomal recessive and neuropathy, hereditary, with liability to pressure palsies, and has symptoms including seizures, tremor and back pain. An important gene associated with Neuropathy is NEFL (Neurofilament Light Chain), and among its related pathways/superpathways is Neural Crest Differentiation. The drugs Acetaminophen and Tramadol have been mentioned in the context of this disorder. Affiliated tissues include nerves, skin and spinal cord, and related phenotypes are behavior/neurological and growth/size/body region

Related Diseases for Neuropathy

Diseases in the Neuropathy family:

Autoimmune Neuropathy Hereditary Neuropathies

Diseases related to Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2797)
# Related Disease Score Top Affiliating Genes
1 neuropathy, congenital hypomyelinating, 1, autosomal recessive 33.7 SLC12A6 PMP22 PMP2 NEFL MPZ MFN2
2 neuropathy, hereditary, with liability to pressure palsies 33.6 PMP22 MPZ MFN2 GJB1 GDAP1
3 sensory peripheral neuropathy 33.6 SPTLC1 SLC12A6 SCN11A PMP22 MPZ MFN2
4 peripheral nervous system disease 33.6 SPTLC1 SCN11A PMP22 PMP2 PEX6 NEFL
5 neuropathy, hereditary sensory and autonomic, type iia 33.6 WNK1 SPTLC1 SLC12A6 GDAP1
6 hypertrophic neuropathy of dejerine-sottas 33.6 SPTLC1 PMP22 NEFL MPZ MFN2 GJB1
7 charcot-marie-tooth disease 33.4 WNK1 SPTLC1 SLC12A6 SCN11A PMP22 PMP2
8 charcot-marie-tooth disease, x-linked dominant, 1 33.3 SPTLC1 PMP22 NEFL MPZ MFN2 GJB1
9 neuropathy, hereditary sensory and autonomic, type v 33.3 WNK1 SPTLC1 SCN11A
10 charcot-marie-tooth disease, axonal, type 2e 33.3 SPTLC1 SLC12A6 PMP22 NEFL MPZ MFN2
11 charcot-marie-tooth disease and deafness 33.3 SPTLC1 PMP22 PMP2 NEFL MPZ MFN2
12 charcot-marie-tooth disease, demyelinating, type 1a 33.3 SPTLC1 PMP22 NEFL MPZ MFN2 GJB1
13 charcot-marie-tooth disease, demyelinating, type 1b 33.2 PMP22 NEFL MPZ MFN2 GJB1 GDAP1
14 autonomic neuropathy 33.2 WNK1 SPTLC1 SCN11A
15 hereditary neuropathies 33.2 PMP22 MPZ MFN2 LMNA GJB1
16 optic nerve disease 33.1 NEFL MFN2 GDAP1
17 charcot-marie-tooth disease, axonal, type 2b 33.1 SPTLC1 NEFL MPZ MFN2 GJB1 GDAP1
18 giant axonal neuropathy 33.1 NEFL GAN
19 neuropathy, hereditary sensory and autonomic, type ia 33.1 WNK1 SPTLC1
20 hereditary motor and sensory neuropathy, type iic 33.1 NEFL MPZ MFN2 GJB1 GDAP1
21 charcot-marie-tooth disease, demyelinating, type 1c 33.1 PMP22 NEFL MPZ MFN2 GJB1 GDAP1
22 peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease 33.1 PMP22 MPZ GJB1
23 neuronopathy, distal hereditary motor, type va 33.0 MFN2 HARS1 GDAP1
24 polyneuropathy 33.0 PMP22 MPZ MFN2 LMNA GJB1 GDAP1
25 axonal neuropathy 33.0 PMP22 NEFL MFN2 LMNA GDAP1 GAN
26 charcot-marie-tooth disease, axonal, type 2d 32.9 SPTLC1 PMP22 NEFL MPZ MFN2 GJB1
27 charcot-marie-tooth disease, type 4b2 32.9 NEFL MPZ MFN2 GJB1 GDAP1 GAN
28 charcot-marie-tooth disease, type 4a 32.9 PMP2 MPZ MFN2 GJB1 GDAP1
29 autoimmune peripheral neuropathy 32.9 PMP2 MPZ GJB1
30 charcot-marie-tooth disease, dominant intermediate a 32.9 MPZ GJB1 GDAP1
31 charcot-marie-tooth disease, type 4d 32.9 MPZ GJB1 GDAP1
32 charcot-marie-tooth disease, axonal, type 2a1 32.9 MPZ MFN2 GDAP1
33 charcot-marie-tooth disease, demyelinating, type 1d 32.8 PMP22 PMP2 MPZ GJB1 GDAP1
34 charcot-marie-tooth disease, axonal, type 2b2 32.8 NEFL MPZ MFN2 GDAP1
35 guillain-barre syndrome 32.8 PMP22 PMP2 MPZ
36 charcot-marie-tooth disease, x-linked recessive, 2 32.8 MPZ MFN2 GJB1
37 charcot-marie-tooth disease, axonal, type 2t 32.8 SLC12A6 GDAP1 GAN
38 charcot-marie-tooth disease, axonal, type 2w 32.8 MPZ HARS1 GJB1 GDAP1
39 motor peripheral neuropathy 32.8 SLC12A6 PMP22 MFN2
40 charcot-marie-tooth disease, axonal, type 2p 32.7 SLC12A6 GDAP1 GAN
41 charcot-marie-tooth disease, axonal, type 2f 32.7 NEFL MPZ MFN2 GJB1 GDAP1
42 charcot-marie-tooth disease, axonal, type 2j 32.7 NEFL MPZ GDAP1
43 charcot-marie-tooth disease, axonal, type 2b1 32.7 MFN2 LMNA GDAP1
44 charcot-marie-tooth disease, demyelinating, type 1f 32.7 NEFL MPZ GJB1 GDAP1
45 charcot-marie-tooth disease, recessive intermediate a 32.6 MFN2 GDAP1
46 brachial plexus neuropathy 32.6 PMP22 MPZ GJB1
47 charcot-marie-tooth disease, axonal, type 2l 32.6 SPTLC1 NEFL MPZ MFN2 GDAP1
48 charcot-marie-tooth disease, type 4c 32.6 MPZ GJB1 GDAP1
49 charcot-marie-tooth disease, dominant intermediate c 32.6 SPTLC1 MPZ GJB1 GDAP1
50 charcot-marie-tooth disease, axonal, type 2i 32.5 NEFL MPZ GJB1 GDAP1

Graphical network of the top 20 diseases related to Neuropathy:



Diseases related to Neuropathy

Symptoms & Phenotypes for Neuropathy

UMLS symptoms related to Neuropathy:


seizures; tremor; back pain; headache; syncope; hemiparesis; pain; chronic pain; sciatica; vertigo/dizziness; sleeplessness; neuralgia; neurologic symptoms; atypical facial pain

MGI Mouse Phenotypes related to Neuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 AIFM1 GAN GDAP1 GJB1 HFE LMNA
2 growth/size/body region MP:0005378 10.07 AIFM1 DIAPH3 GAN GJB1 HFE IARS2
3 cellular MP:0005384 10.06 AIFM1 DIAPH3 GAN GDAP1 GJB1 HFE
4 mortality/aging MP:0010768 9.97 AIFM1 DIAPH3 GAN GJB1 HFE IARS2
5 nervous system MP:0003631 9.53 AIFM1 DIAPH3 GAN GDAP1 GJB1 HFE
6 muscle MP:0005369 9.5 AIFM1 GAN LMNA MFN2 PMP22 SLC12A6

Drugs & Therapeutics for Neuropathy

Drugs for Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 463)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
3
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
4
Mexiletine Approved, Investigational Phase 4 31828-71-4 4178
5
Nortriptyline Approved Phase 4 72-69-5 4543
6
tannic acid Approved Phase 4 1401-55-4
7
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
8
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
9
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
10
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
11
Carbidopa Approved Phase 4 28860-95-9 34359
12
Levodopa Approved Phase 4 59-92-7 6047
13
Sodium citrate Approved, Investigational Phase 4 68-04-2
14
4-Aminopyridine Approved Phase 4 504-24-5 1727
15
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
16
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
17
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
18
Amitriptyline Approved Phase 4 50-48-6 2160
19
Memantine Approved, Investigational Phase 4 19982-08-2 4054
20
Topiramate Approved Phase 4 97240-79-4 5284627
21
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
22
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
23
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
24
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
25
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
26
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
27
Rizatriptan Approved Phase 4 145202-66-0, 144034-80-0 5078
28
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
29
Propranolol Approved, Investigational Phase 4 525-66-6 4946
30
Levetiracetam Approved Phase 4 102767-28-2 441341
31
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
32
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
33
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
34
Norepinephrine Approved Phase 4 51-41-2 439260
35
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
36
Tapentadol Approved Phase 4 175591-23-8 9838022
37
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
38
Donepezil Approved Phase 4 120014-06-4 3152
39
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
40
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
41
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4 54-47-7 1051
42
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
43
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
44
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
45 Narcotics Phase 4
46 Analgesics, Opioid Phase 4
47 Antipyretics Phase 4
48 Vitamin B9 Phase 4
49 Nutrients Phase 4
50 Trace Elements Phase 4

Interventional clinical trials:

(show top 50) (show all 1121)
# Name Status NCT ID Phase Drugs
1 The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair Unknown status NCT02419443 Phase 4 Gabapentin;Placebo
2 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
3 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
4 Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN) Unknown status NCT01770964 Phase 4 Pregabalin;placebo
5 The Effects of Omega-3 Fatty Acids on Chemotherapy-induced Neuropathy and Inflammation in Patients With Breast Cancer Unknown status NCT01049295 Phase 4
6 An Open-label, Randomized, Multi-center Clinical Trial to Evaluate the Safety and Efficacy in Peripheral Neuropathies Patients Treated With Mecobalamin Injection Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
7 A Multicenter Trial Evaluating the Safety and Efficacy of Cesamet™ for the Symptomatic Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer Completed NCT00380965 Phase 4 Cesamet™ (nabilone)
8 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
9 A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
10 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS) Completed NCT02260388 Phase 4 Nortriptyline;Duloxetine;Pregabalin;Mexiletine
11 Clinical Outcomes for Diabetic Foot Ulcers Treated With Clostridial Collagenase (SANTYL®) Ointment or With a Comparator Product Containing Silver Completed NCT02581488 Phase 4
12 Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty: A Double-blinded Randomized Control Trial Completed NCT03271151 Phase 4 Cymbalta
13 An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
14 A Randomized, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Profiles of Two Formulation of Pregabalin in Healthy Volunteers Under Fasting Conditions Completed NCT03712475 Phase 4 Pregabalin
15 Evaluation of a Structured Algorithm for Intrathecal Bolus Doses of Ziconotide (Prialt®)- The Swedish Ziconotide Bolus Study Completed NCT01373983 Phase 4 Ziconotide
16 Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy: A Randomized, Double Blind, Placebo Controlled, Multi Center Trial Completed NCT02923388 Phase 4 Injection Mecobalamin,;Tablet Pyridoxine hydrochloride;Intravenous normal saline 1 ml;Placebo pill
17 A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN). Completed NCT00156078 Phase 4 pregabalin
18 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
19 A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
20 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
21 A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
22 A Prospective, Open Label, Multi-Center, Study Of Pregabalin In The Treatment Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, HIV-Related Peripheral Neuropathic Pain And Chemotherapy Induced Peripheral Neuropathic Pain Completed NCT00407511 Phase 4 Pregabalin
23 High-dose Vitamin D Supplementation Reduces Inflammation and Improves Microcirculation in Patients With Diabetic Peripheral Neuropathy Completed NCT04377399 Phase 4 Vitamin D
24 A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy Who Need Opioid Combination Treatment With Existing Pregabalin Treatment Completed NCT01675531 Phase 4 Targin
25 The Association of Alpha Lipoic Acid to the Median Nerve Decompression in the Carpal Tunnel Syndrome: a Randomized Controlled Trial. Completed NCT01895621 Phase 4
26 Gabapentin as an Adjunct for Pain Management During Dilation and Evacuation: A Double-blind Randomized Controlled Trial Completed NCT03635905 Phase 4 Gabapentin;Placebo
27 Phase 4 Study of Evaluation of Neural Conduction Along the Visual Pathways Before and After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases Completed NCT00404729 Phase 4 Citicoline
28 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
29 Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy Completed NCT00432393 Phase 4 levodopa-carbidopa
30 Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Completed NCT01975324 Phase 4 dalfampridine;Placebo
31 An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
32 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
33 A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy Completed NCT03914404 Phase 4 γ-linoleic acid and placebo(Thioctic Acid);Thioctic Acid and placebo(γ-linoleic acid)
34 Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies Completed NCT02842554 Phase 4 Drug Placebo Administration
35 A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00266643 Phase 4 duloxetine hydrochloride
36 A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
37 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
38 Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading Completed NCT02439879 Phase 4 Alpha lipoic acid
39 Clinical Study for Assessment of the Efficacy of Gabapentin (Carbatin and Neurontin) in Patients With Neuropathy Pain Completed NCT02074267 Phase 4 Carbatin;Neurontin
40 Comparative Evaluation of Standard Wearing Shoes With Rocker Sole Shoes in Diabetic Patients With Neuropathy Completed NCT02891928 Phase 4
41 Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects Completed NCT02682901 Phase 4 Cycloset;Placebo
42 Efficacy of Pregabalin in Patients With Radicular Pain Completed NCT00908375 Phase 4 Pregabalin;Sugar Pill
43 Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
44 Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT00322621 Phase 4 Duloxetine
45 A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disorder. The Primary Objective of This Study is to Evaluate Whether the Efficacy of Duloxetine Given as 60 mg to 120 mg Once Daily (QD), Measured by the BPI Interference Score After 12 Weeks Shows a Clinically Relevant Improvement in the DPNP Patients With Co-morbid MDD Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
46 An Open, Multicenter Study on the Efficacy, Safety and Tolerability of Gabapentin, Titrated for Reaching an Effect for the Treatment of the Painful Diabetic Neuropathy Completed NCT00644748 Phase 4 gabapentin
47 A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
48 Phase IV Open Non Comparative Trial to Evaluate Efficacy and Safety of Tegretol® in Diabetes Neuropathy Pain. Completed NCT01089855 Phase 4 Carbamazepine
49 A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
50 A Prospective, Open-label Trial of Lidoderm® (Lidocaine Patch 5%)in Painful Diabetic and Idiopathic Neuropathy. Completed NCT00903851 Phase 4 Lidoderm

Search NIH Clinical Center for Neuropathy

Genetic Tests for Neuropathy

Anatomical Context for Neuropathy

The Foundational Model of Anatomy Ontology organs/tissues related to Neuropathy:

19
Nerves

MalaCards organs/tissues related to Neuropathy:

40
Skin, Spinal Cord, Eye, Bone Marrow, Endothelial, Thyroid, Colon

Publications for Neuropathy

Articles related to Neuropathy:

(show top 50) (show all 40858)
# Title Authors PMID Year
1
Exome Sequence Analysis Suggests that Genetic Burden Contributes to Phenotypic Variability and Complex Neuropathy. 6 61
26257172 2015
2
NGLY1 mutation causes neuromotor impairment, intellectual disability, and neuropathy. 61 6
25220016 2015
3
Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome. 61 6
25130867 2014
4
MicroRNA-based therapeutics for optic neuropathy: opportunities and challenges. 61
33642375 2021
5
Transplantation of engineered exosomes derived from bone marrow mesenchymal stromal cells ameliorate diabetic peripheral neuropathy under electrical stimulation. 61
33553812 2021
6
Hepatocyte growth factor is necessary for efficient outgrowth of injured peripheral axons in in vitro culture system and in vivo nerve crush mouse model. 61
33718632 2021
7
Simultaneous T1 , T2 , and T1ρ relaxation mapping of the lower leg muscle with MR fingerprinting. 61
33554369 2021
8
Tacrolimus induced optic neuropathy in post-lung transplant patients: A series of 3 patients. 61
33778180 2021
9
Asymmetric optic disc edema in a young patient with POEMS: A rare presentation of a rare disease. 61
33786404 2021
10
Reduced neuropathy target esterase in pre-eclampsia suppresses tube formation of HUVECs via dysregulation of phospholipid metabolism. 61
33184906 2021
11
Medium-term outcomes of multi-disciplinary surgical management of non-ischemic diabetic heel ulcers. 61
33717969 2021
12
The current burden of diabetic foot disease. 61
33680841 2021
13
Gene expression profiles of diabetic kidney disease and neuropathy in eNOS knockout mice: Predictors of pathology and RAS blockade effects. 61
33788970 2021
14
Prospects for the application of transcranial magnetic stimulation in diabetic neuropathy. 61
33229735 2021
15
SARM1 is required in human derived sensory neurons for injury-induced and neurotoxic axon degeneration. 61
33548217 2021
16
Immune-mediated vincristine-induced neuropathy: Unlocking therapies. 61
33751022 2021
17
Vincristine-induced peripheral neuropathy is driven by canonical NLRP3 activation and IL-1β release. 61
33656514 2021
18
Increased thalamo-cortical functional connectivity in patients with diabetic painful neuropathy: A resting-state functional MRI study. 61
33791018 2021
19
M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia. 61
33210289 2021
20
Characterization of the anti-α-Gal antibody profile in association with Guillain-Barré syndrome, implications for tick-related allergic reactions. 61
33465663 2021
21
Hematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalopathy: A single-center experience underscoring the multiple factors involved in the prognosis. 61
33533561 2021
22
Tau associated peripheral and central neurodegeneration: Identification of an early imaging marker for tauopathy. 61
33482356 2021
23
Clinical and Molecular Features of POLG-Related Sensory Ataxic Neuropathy with Dysarthria and Ophthalmoparesis. 61
33791913 2021
24
Letter to the Editor Regarding "Ulnar Neuropathy Caused by a Muscular Arcade of Struthers". 61
33770838 2021
25
Human HINT1 Mutant Proteins that Cause Axonal Motor Neuropathy Exhibit Anomalous Interactions with Partner Proteins. 61
33404983 2021
26
Broadening the genetic spectrum of distal hereditary motor neuropathy. 61
33449405 2021
27
Subcutaneous immunoglobulin dose titration to clinical response in inflammatory neuropathy. 61
33608795 2021
28
Ischemic Monomelic Neuropathy after Percutaneous Arteriovenous Fistula Creation. 61
33483227 2021
29
Determination of the transcriptional level of long non-coding RNA NEAT-1, downstream target microRNAs, and genes targeted by microRNAs in diabetic neuropathy patients. 61
33508370 2021
30
Satellite glia as a critical component of diabetic neuropathy: Role of lipocalin-2 and pyruvate dehydrogenase kinase-2 axis in the dorsal root ganglion. 61
33251681 2021
31
Point process models for sweat gland activation observed with noise. 61
33517587 2021
32
Neuroprotective effect of paeonol in streptozotocin-induced diabetes in rats. 61
33577853 2021
33
Correction to: A placebo‑controlled, double‑blind, randomized study of recombinant thrombomodulin (ART‑123) to prevent oxaliplatin‑induced peripheral neuropathy. 61
33136172 2021
34
CE: Chemotherapy-Induced Peripheral Neuropathy. 61
33735114 2021
35
Melittin, a honeybee venom derived peptide for the treatment of chemotherapy-induced peripheral neuropathy. 61
33796975 2021
36
Effects of the food additive monosodium glutamate on cisplatin-induced gastrointestinal dysmotility and peripheral neuropathy in the rat. 61
33112027 2021
37
Diabetic peripheral neuropathy: Person-centered care. 61
33759862 2021
38
Effectiveness and safety of low-level laser therapy in diabetic peripheral neuropathy: a protocol for a systematic review and meta-analysis. 61
33810813 2021
39
Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing. 61
33507480 2021
40
Diabetic peripheral neuropathy: Person-centered care. 61
33759861 2021
41
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. 61
32273476 2021
42
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. 61
33721562 2021
43
Human immunodeficiency virus-related peripheral neuropathy: A systematic review and meta-analysis. 61
33226721 2021
44
Dorsal Root Ganglion Stimulation for Treatment of Chemotherapy-Induced Neuropathy. 61
32701635 2021
45
Peripheral nerves are involved in hypomyelinating leukodystrophy-3 caused by a homozygous AIMP1 variant. 61
33402283 2021
46
Altered plasma serine and 1-deoxydihydroceramide profiles are associated with diabetic neuropathy in type 2 diabetes and obesity. 61
33485750 2021
47
Nuclear DNA Mutation Causing a Phenotypic Leber Hereditary Optic Neuropathy Plus. 61
32918965 2021
48
High-resolution MR imaging of cranial neuropathy in patients with anti-GQ1b antibody syndrome. 61
33677393 2021
49
Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis. 61
33354901 2021
50
One nerve suffices: A clinically guided nerve ultrasound protocol for the differentiation of multifocal motor neuropathy (MMN) and amyotrophic lateral sclerosis (ALS). 61
33355881 2021

Variations for Neuropathy

ClinVar genetic disease variations for Neuropathy:

6 (show top 50) (show all 102)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 IARS2 NM_018060.4(IARS2):c.2726C>T (p.Pro909Leu) SNV Pathogenic 156553 rs587783070 GRCh37: 1:220316451-220316451
GRCh38: 1:220143109-220143109
2 PEX6 NM_000287.4(PEX6):c.371T>C (p.Leu124Pro) SNV Pathogenic 869197 GRCh37: 6:42946518-42946518
GRCh38: 6:42978780-42978780
3 PEX6 NM_000287.4(PEX6):c.2356C>T (p.Arg786Trp) SNV Pathogenic 553552 rs267608239 GRCh37: 6:42933788-42933788
GRCh38: 6:42966050-42966050
4 HARS1 NM_002109.6(HARS1):c.616G>T (p.Asp206Tyr) SNV Pathogenic 804285 rs1131040 GRCh37: 5:140057507-140057507
GRCh38: 5:140677922-140677922
5 HARS1 NM_002109.6(HARS1):c.730delG Deletion Pathogenic 804286 rs1581505917 GRCh37: 5:140057005-140057005
GRCh38: 5:140677420-140677420
6 NEFL NM_006158.5(NEFL):c.64C>T (p.Pro22Ser) SNV Pathogenic 14029 rs28928910 GRCh37: 8:24813966-24813966
GRCh38: 8:24956452-24956452
7 HFE NM_000410.3(HFE):c.845G>A (p.Cys282Tyr) SNV Pathogenic 9 rs1800562 GRCh37: 6:26093141-26093141
GRCh38: 6:26092913-26092913
8 COX6A1 NM_004373.4(COX6A1):c.103+1G>C SNV Likely pathogenic 560368 rs377504835 GRCh37: 12:120876033-120876033
GRCh38: 12:120438230-120438230
9 NEFL NM_006158.5(NEFL):c.64C>T (p.Pro22Ser) SNV Likely pathogenic 14029 rs28928910 GRCh37: 8:24813966-24813966
GRCh38: 8:24956452-24956452
10 CHRNG NM_005199.5(CHRNG):c.256C>T (p.Arg86Cys) SNV Likely pathogenic 397615 rs777219451 GRCh37: 2:233405327-233405327
GRCh38: 2:232540617-232540617
11 GJB1 NM_000166.6(GJB1):c.218A>G (p.His73Arg) SNV Likely pathogenic 1004038 GRCh37: X:70443775-70443775
GRCh38: X:71223925-71223925
12 NGLY1 NM_018297.4(NGLY1):c.1533_1536del (p.Asn511fs) Deletion Likely pathogenic 548658 rs765211108 GRCh37: 3:25770699-25770702
GRCh38: 3:25729208-25729211
13 LMNA NM_170707.4(LMNA):c.344A>T (p.Glu115Val) SNV Likely pathogenic 200932 rs794728588 GRCh37: 1:156085053-156085053
GRCh38: 1:156115262-156115262
14 DNAJB5 NM_001135005.3(DNAJB5):c.43C>T (p.Pro15Ser) SNV Likely pathogenic 243086 rs774909609 GRCh37: 9:34990670-34990670
GRCh38: 9:34990673-34990673
15 PMP2 NM_002677.5(PMP2):c.128T>A (p.Ile43Asn) SNV Likely pathogenic 243087 rs879253869 GRCh37: 8:82357170-82357170
GRCh38: 8:81444935-81444935
16 SPTLC3 NM_018327.4(SPTLC3):c.448T>C (p.Trp150Arg) SNV Likely pathogenic 243088 rs755919784 GRCh37: 20:13053048-13053048
GRCh38: 20:13072400-13072400
17 MT-ND4 NC_012920.1:m.11896C>G SNV Uncertain significance 370054 rs1057516065 GRCh37: MT:11896-11896
GRCh38: MT:11896-11896
18 ABCA4 NM_000350.3(ABCA4):c.203C>T (p.Pro68Leu) SNV Uncertain significance 99113 rs62654397 GRCh37: 1:94577093-94577093
GRCh38: 1:94111537-94111537
19 PNPLA6 NM_001166114.2(PNPLA6):c.1205C>T (p.Ser402Leu) SNV Uncertain significance 397619 rs372193709 GRCh37: 19:7606906-7606906
GRCh38: 19:7542020-7542020
20 PRX NM_020956.2(PRX):c.*2540G>A SNV Uncertain significance 397620 rs369505684 GRCh37: 19:40901924-40901924
GRCh38: 19:40396017-40396017
21 KIFBP NM_015634.4(KIFBP):c.167_187dup (p.Asp56_Glu62dup) Duplication Uncertain significance 397616 rs767103634 GRCh37: 10:70748746-70748747
GRCh38: 10:68988990-68988991
22 PHKA1 NM_002637.4(PHKA1):c.1272T>A (p.Asp424Glu) SNV Uncertain significance 397618 rs1060499719 GRCh37: X:71870292-71870292
GRCh38: X:72650442-72650442
23 KIF24 Deletion Uncertain significance 243059 GRCh37: 9:34280042-34296294
GRCh38: 9:34280044-34296296
24 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33243C>G SNV Uncertain significance 461796 rs140274429 GRCh37: 11:63885468-63885468
GRCh38: 11:64117996-64117996
25 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34761C>G SNV Uncertain significance 530933 rs777177875 GRCh37: 11:63883950-63883950
GRCh38: 11:64116478-64116478
26 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34449C>T SNV Uncertain significance 530935 rs148012979 GRCh37: 11:63884262-63884262
GRCh38: 11:64116790-64116790
27 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33260C>A SNV Uncertain significance 530936 rs143309484 GRCh37: 11:63885451-63885451
GRCh38: 11:64117979-64117979
28 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34743C>T SNV Uncertain significance 530937 rs770193280 GRCh37: 11:63883968-63883968
GRCh38: 11:64116496-64116496
29 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34934G>A SNV Uncertain significance 530938 rs139768227 GRCh37: 11:63883777-63883777
GRCh38: 11:64116305-64116305
30 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33617C>T SNV Uncertain significance 530939 rs150825004 GRCh37: 11:63885094-63885094
GRCh38: 11:64117622-64117622
31 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33852C>G SNV Uncertain significance 530941 rs138445479 GRCh37: 11:63884859-63884859
GRCh38: 11:64117387-64117387
32 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33881C>T SNV Uncertain significance 565723 rs767022154 GRCh37: 11:63884830-63884830
GRCh38: 11:64117358-64117358
33 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33604C>A SNV Uncertain significance 566560 rs1395376914 GRCh37: 11:63885107-63885107
GRCh38: 11:64117635-64117635
34 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33719C>T SNV Uncertain significance 568577 rs769032516 GRCh37: 11:63884992-63884992
GRCh38: 11:64117520-64117520
35 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34898_517+34918del Deletion Uncertain significance 571356 rs1565240655 GRCh37: 11:63883793-63883813
GRCh38: 11:64116321-64116341
36 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33243C>T SNV Uncertain significance 575806 rs140274429 GRCh37: 11:63885468-63885468
GRCh38: 11:64117996-64117996
37 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34250T>A SNV Uncertain significance 577882 rs1565241569 GRCh37: 11:63884461-63884461
GRCh38: 11:64116989-64116989
38 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34535G>A SNV Uncertain significance 579757 rs756250929 GRCh37: 11:63884176-63884176
GRCh38: 11:64116704-64116704
39 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33906T>G SNV Uncertain significance 640772 rs1590933528 GRCh37: 11:63884805-63884805
GRCh38: 11:64117333-64117333
40 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34305T>C SNV Uncertain significance 643512 rs1590932597 GRCh37: 11:63884406-63884406
GRCh38: 11:64116934-64116934
41 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33198G>A SNV Uncertain significance 645543 rs375487485 GRCh37: 11:63885513-63885513
GRCh38: 11:64118041-64118041
42 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34236G>A SNV Uncertain significance 647420 rs756527574 GRCh37: 11:63884475-63884475
GRCh38: 11:64117003-64117003
43 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33328C>A SNV Uncertain significance 658157 rs1590934834 GRCh37: 11:63885383-63885383
GRCh38: 11:64117911-64117911
44 MYBPC3 NM_000256.3(MYBPC3):c.3614G>A (p.Arg1205Gln) SNV Uncertain significance 181014 rs730880596 GRCh37: 11:47354130-47354130
GRCh38: 11:47332579-47332579
45 KCNJ10 NM_002241.5(KCNJ10):c.967T>C (p.Tyr323His) SNV Uncertain significance 816536 rs1571265188 GRCh37: 1:160011356-160011356
GRCh38: 1:160041566-160041566
46 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34501G>T SNV Uncertain significance 842634 GRCh37: 11:63884210-63884210
GRCh38: 11:64116738-64116738
47 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33197C>T SNV Uncertain significance 845837 GRCh37: 11:63885514-63885514
GRCh38: 11:64118042-64118042
48 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34527G>A SNV Uncertain significance 948270 GRCh37: 11:63884184-63884184
GRCh38: 11:64116712-64116712
49 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34391G>A SNV Uncertain significance 957887 GRCh37: 11:63884320-63884320
GRCh38: 11:64116848-64116848
50 FLRT1 , MACROD1 NM_013280.5(FLRT1):c.389G>A (p.Arg130Gln) SNV Uncertain significance 1002428 GRCh37: 11:63884128-63884128
GRCh38: 11:64116656-64116656

Copy number variations for Neuropathy from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 107544 17 15900000 22100000 Microdeletion Neuropathy
2 107574 17 16000000 22200000 Copy number Neuropathy
3 216423 6 92100000 98700000 Microdeletion EPHA7 Neuropathy

Expression for Neuropathy

Search GEO for disease gene expression data for Neuropathy.

Pathways for Neuropathy

Pathways related to Neuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.81 PMP22 MPZ GJB1

GO Terms for Neuropathy

Biological processes related to Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial fusion GO:0008053 8.62 MFN2 GDAP1

Sources for Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....